

SEQUENCE LISTING

<110> Biotest AG
Dana-Farber Cancer Institute, Inc.
ImmunoGen, Inc.

<120> METHODS AND AGENTS FOR IMPROVING TARGETING OF CD138 EXPRESSING
TUMOR CELLS

<130> 319932.WO/JND/CJS

<150> 61/016,614
<151> 2007-12-26

<150> 61/087,466
<151> 2008-08-08

<150> 61/087,590
<151> 2008-08-08

<160> 13

<170> PatentIn version 3.5

<210> 1
<211> 448
<212> PRT
<213> Artificial Sequence

<220>
<223> Amino Acid sequence (predicted) of heavy chain of chimeric
human/mouse antibody

<220>
<221> CDR1
<222> (31) .. (35)

<220>
<221> CDR2
<222> (51) .. (68)

<220>
<221> CDR3
<222> (99) .. (111)

<220>
<221> region IgG4
<222> (123) .. (448)

<400> 1

Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Met Met Pro Gly Ala
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Asn Tyr
20 25 30

Trp Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile

35					40					45					
Gly	Glu	Ile	Leu	Pro	Gly	Thr	Gly	Arg	Thr	Ile	Tyr	Asn	Glu	Lys	Phe
50					55					60					
Lys	Gly	Lys	Ala	Thr	Phe	Thr	Ala	Asp	Ile	Ser	Ser	Asn	Thr	Val	Gln
65					70					75					80
Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Tyr	Cys
				85					90					95	
Ala	Arg	Arg	Asp	Tyr	Tyr	Gly	Asn	Phe	Tyr	Tyr	Ala	Met	Asp	Tyr	Trp
			100					105					110		
Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro
		115					120					125			
Ser	Val	Phe	Pro	Leu	Ala	Pro	Cys	Ser	Arg	Ser	Thr	Ser	Glu	Ser	Thr
	130					135					140				
Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr
145					150					155					160
Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro
			165						170					175	
Ala	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr
			180					185					190		
Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Lys	Thr	Tyr	Thr	Cys	Asn	Val	Asp
		195					200					205			
His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Ser	Lys	Tyr
	210					215					220				
Gly	Pro	Pro	Cys	Pro	Ser	Cys	Pro	Ala	Pro	Glu	Phe	Leu	Gly	Gly	Pro
225					230					235					240
Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser
				245					250					255	
Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	Gln	Glu	Asp
			260					265					270		
Pro	Glu	Val	Gln	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn
		275					280					285			

Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val
290 295 300

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu
305 310 315 320

Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys
325 330 335

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr
340 345 350

Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr
355 360 365

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
370 375 380

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu
385 390 395 400

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys
405 410 415

Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu
420 425 430

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly
435 440 445

<210> 2
<211> 214
<212> PRT
<213> Artificial Sequence

<220>
<223> Amino Acid sequence (predicted) of light chain of chimeric
human/mouse antibody

<220>
<221> CDR1
<222> (24) .. (34)

<220>
<221> CDR2
<222> (50) .. (56)

<220>

<221> CDR3
<222> (89)..(97)

<220>
<221> region IgG4
<222> (108)..(214)

<400> 2

Asp Ile Gln Met Thr Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15

Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Asn Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Glu Leu Leu Ile
35 40 45

Tyr Tyr Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
65 70 75 80

Glu Asp Ile Gly Thr Tyr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Arg
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110

Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125

Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160

Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175

Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

Phe Asn Arg Gly Glu Cys
210

<210> 3
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> IgH primer MHV7

<400> 3
atgggcatca agatggagtc acagacccag g 31

<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> IgG1 constant region primer MHCG1

<400> 4
cagtggatag acagatgggg g 21

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Ig kappa primer MKV2

<400> 5
atggagacag acacactcct gctatgggtg 30

<210> 6
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Ig kappa primer MKV4

<400> 6
atgagggcc ctgctcagtt ttttggttc ttg 33

<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Ig kappa primer MKV9

<400> 7

atggtatcca cacctcagtt ccttg	25
<210> 8	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> primer MKC	
<400> 8	
actggatggt gggaagatgg	20
<210> 9	
<211> 50	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> forward (For) primer	
<400> 9	
agagaagctt gccgccacca tgattgctc tgctcagttc cttggtctcc	50
<210> 10	
<211> 35	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> oligonucleotide primer BT03	
<400> 10	
caacagtata gtaagctccc tcggacgttc ggtgg	35
<210> 11	
<211> 35	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> oligonucleotide primer BT04	
<400> 11	
ccaccgaacg tccgaggag cttactatac tgttg	35
<210> 12	
<211> 41	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> primer g2258	
<400> 12	
cgcggatcc actcacgttt gatttccagc ttggtgcctc c	41

<210> 13
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer g22949

<400> 13
cgatgggcc ttggtggagg ctgaggagac ggtgactgag gttcc